TriaGen Wealth Management LLC Invests $1.40 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TriaGen Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,334 shares of the biopharmaceutical company’s stock, valued at approximately $1,402,000.

Several other hedge funds have also added to or reduced their stakes in the business. Raymond James & Associates lifted its stake in Regeneron Pharmaceuticals by 10.5% in the third quarter. Raymond James & Associates now owns 82,006 shares of the biopharmaceutical company’s stock worth $86,208,000 after purchasing an additional 7,778 shares during the last quarter. Slow Capital Inc. lifted its stake in Regeneron Pharmaceuticals by 2.0% in the third quarter. Slow Capital Inc. now owns 12,355 shares of the biopharmaceutical company’s stock worth $12,988,000 after purchasing an additional 241 shares during the last quarter. Friedenthal Financial purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $50,000. Capital Investment Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 6.8% in the third quarter. Capital Investment Advisors LLC now owns 315 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 20 shares during the period. Finally, Blue Trust Inc. increased its position in shares of Regeneron Pharmaceuticals by 83.0% in the third quarter. Blue Trust Inc. now owns 518 shares of the biopharmaceutical company’s stock valued at $544,000 after acquiring an additional 235 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 9th. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Finally, Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,116.00.

Regeneron Pharmaceuticals Stock Down 0.8 %

Shares of REGN traded down $7.55 during mid-day trading on Friday, hitting $990.68. The company’s stock had a trading volume of 869,228 shares, compared to its average volume of 496,271. The firm has a market capitalization of $109.21 billion, a price-to-earnings ratio of 26.24, a PEG ratio of 3.45 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company’s 50-day moving average is $1,109.58 and its 200-day moving average is $1,039.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the previous year, the firm posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.